Endocrinology Drugs Market: By Drug Class (Antidiabetic drugs, Thyroid drugs, Steroid Hormones, Hypothalamic and Pituitary Hormones, Others), By Indication (Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary gland Disorders, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

Endocrinology Drugs Market size was valued at USD 32,642.9 million in 2023 and is poised to grow at an 8.5% CAGR from 2024 to 2030. Endocrinology drugs regulate the synthesis, and release of hormones from their respective glands to achieve hormonal balance. The endocrinology drugs market is expected to grow over the forecast years due to an increase in the R&D activities for the development of novel molecules, a growing number of adolescents with hormonal imbalances, and an increase in the prevalence of endocrine disorders. Moreover, increasing rates of endocrine disorders such as diabetes are a primary driver of the endocrinology drugs market growth. For instance, according to the International Diabetic Foundation (IDF) 2021, approximately 537 million adults (20–79 years old) have diabetes in 2021 and it is expected to reach 643 million individuals worldwide by 2030.

Additionally endocrine drugs market will grow in the future years due to the development of novel molecules by key manufacturers across the globe. However, the endocrine drugs market is anticipated to be stifled by the stringent regulatory framework for the marketing and approval of endocrinology drugs, the high cost of R&D, and patent expiry of drugs. Moreover, advancements in technology and devices can be a restraint to the endocrinology drugs market. For instance, in January 2024, the USFDA granted clearance for the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia — a wearable belt device, worn on the hips, that delivers targeted, calibrated vibration to the lumbar spine and hips that Bone Health Technologies is marketing as Osteoboost. The key trends in the endocrine drugs market are continuous technological advancements like patches and painless diabetic injections.

Endocrinology Drugs Market Key Developments:

• In December 2023, Sanofi filed regulatory applications for adult-onset diabetes in Chinaand Japan for Soliflozin, extending the company's reach with SGLT2 inhibitors.
• In March 2024, Alexion, part of AstraZeneca Rare Disease, has agreed to acquire Amolyt Pharma for up to USD 1.05 billion which centers on advancing eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide for the management of hypoparathyroidism.
• In February 2024, Eli Lilly said that it is planning to launch its immensely popular diabetes and obesity medication, Mounjaro- a weight-management supplement known by the chemical name tirzepatide, into the Indian market by the end of 2025